159 related articles for article (PubMed ID: 8289851)
1. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
Rodin A; Thakkar H; Taylor N; Clayton R
N Engl J Med; 1994 Feb; 330(7):460-5. PubMed ID: 8289851
[TBL] [Abstract][Full Text] [Related]
2. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
Tsilchorozidou T; Honour JW; Conway GS
J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
[TBL] [Abstract][Full Text] [Related]
3. 5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase activity in prepubertal Hispanic girls with premature adrenarche.
Silfen ME; Shackleton CH; Manibo AM; Levine LS; Sekhar D; McMahon DJ; Oberfield SE
J Clin Endocrinol Metab; 2002 Oct; 87(10):4647-51. PubMed ID: 12364451
[TBL] [Abstract][Full Text] [Related]
4. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.
Vassiliadi DA; Barber TM; Hughes BA; McCarthy MI; Wass JA; Franks S; Nightingale P; Tomlinson JW; Arlt W; Stewart PM
J Clin Endocrinol Metab; 2009 Sep; 94(9):3558-66. PubMed ID: 19567518
[TBL] [Abstract][Full Text] [Related]
5. Endogenous inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 do not explain abnormal cortisol metabolism in polycystic ovary syndrome.
Walker BR; Rodin A; Taylor NF; Clayton RN
Clin Endocrinol (Oxf); 2000 Jan; 52(1):77-80. PubMed ID: 10651756
[TBL] [Abstract][Full Text] [Related]
6. Hyperandrogenism in polycystic ovary syndrome.
Stewart PM; Edwards CR
N Engl J Med; 1994 Jul; 331(2):131-2. PubMed ID: 8208262
[No Abstract] [Full Text] [Related]
7. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
Barnes RB; Rosenfield RL; Burstein S; Ehrmann DA
N Engl J Med; 1989 Mar; 320(9):559-65. PubMed ID: 2521688
[TBL] [Abstract][Full Text] [Related]
8. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome.
Gambineri A; Forlani G; Munarini A; Tomassoni F; Cognigni GE; Ciampaglia W; Pagotto U; Walker BR; Pasquali R
J Endocrinol Invest; 2009 Mar; 32(3):210-8. PubMed ID: 19542736
[TBL] [Abstract][Full Text] [Related]
9. Ovarian 11β-hydroxysteroid dehydrogenase (11βHSD) activity is suppressed in women with anovulatory polycystic ovary syndrome (PCOS): apparent role for ovarian androgens.
Michael AE; Glenn C; Wood PJ; Webb RJ; Pellatt L; Mason HD
J Clin Endocrinol Metab; 2013 Aug; 98(8):3375-83. PubMed ID: 23678035
[TBL] [Abstract][Full Text] [Related]
10. [Critical study of the characterization of hyperandrogenism in a group of obese women].
Cordray JP; Merceron RE; Nys P; Guillerd X; Reboul P; Rainaut M
Rev Fr Gynecol Obstet; 1995 Oct; 90(10):403-8. PubMed ID: 8539505
[TBL] [Abstract][Full Text] [Related]
11. Polycystic ovarian disease: the adrenal connection.
Marouliss GB; Triantafillidis IK
Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():205-7. PubMed ID: 16641861
[TBL] [Abstract][Full Text] [Related]
12. Increased 5alpha-reductase and normal 11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome.
Chin D; Shackleton C; Prasad VK; Kohn B; David R; Imperato-McGinley J; Cohen H; McMahon DJ; Oberfield SE
J Pediatr Endocrinol Metab; 2000 Mar; 13(3):253-9. PubMed ID: 10714750
[TBL] [Abstract][Full Text] [Related]
13. Concentration of unconjugated adrenogenic hormones and their precursors in normal and polycystic ovaries.
Györy G; Kiss C; Fehér T; Poteczin E
Endokrinologie; 1975 Jan; 64(2):181-90. PubMed ID: 125194
[TBL] [Abstract][Full Text] [Related]
14. [The effects of hyperinsulinmia and insulin-like growth factor-1 on hyperandrogenism in polycystic ovarian syndrome].
Liang X; Zhuang G; Fan Q
Zhonghua Yi Xue Za Zhi; 1997 Apr; 77(4):266-9. PubMed ID: 9596926
[TBL] [Abstract][Full Text] [Related]
15. Cortisol metabolism in the postoperative period after cardiac surgery.
Vogeser M; Felbinger TW; Röll W; Jacob K
Exp Clin Endocrinol Diabetes; 1999; 107(8):539-46. PubMed ID: 10612485
[TBL] [Abstract][Full Text] [Related]
16. 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome.
O'Reilly MW; Kempegowda P; Jenkinson C; Taylor AE; Quanson JL; Storbeck KH; Arlt W
J Clin Endocrinol Metab; 2017 Mar; 102(3):840-848. PubMed ID: 27901631
[TBL] [Abstract][Full Text] [Related]
17. Administration of glycyrrhetinic acid: significant correlation between serum levels and the cortisol/cortisone-ratio in serum and urine.
Heilmann P; Heide J; Hundertmark S; Schöneshöfer M
Exp Clin Endocrinol Diabetes; 1999; 107(6):370-8. PubMed ID: 10543414
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women.
Liou TH; Yang JH; Hsieh CH; Lee CY; Hsu CS; Hsu MI
Fertil Steril; 2009 Dec; 92(6):1960-5. PubMed ID: 18980763
[TBL] [Abstract][Full Text] [Related]
19. 5 alpha-reductase activity in polycystic ovary syndrome.
Stewart PM; Shackleton CH; Beastall GH; Edwards CR
Lancet; 1990 Feb; 335(8687):431-3. PubMed ID: 1968168
[TBL] [Abstract][Full Text] [Related]
20. Increased urinary free cortisol and decreased serum corticosteroid-binding globulin in polycystic ovary syndrome.
Invitti C; Pecori Giraldi F; Dubini A; De Martin M; Cavagnini F
Acta Endocrinol (Copenh); 1991 Jul; 125(1):28-32. PubMed ID: 1872121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
